Speaking about MDUFA, Stephen J. Ubl of AdvaMed said, in the House-related release, “This potentially game-changing user fee agreement includes provisions that will strengthen accountability measures provide additional FDA resources. And under the agreement, the FDA is presented with an opportunity to improve its predictability, consistency and efficiency, while continuing to adhere to its high standard for product approval.”
With the two versions of the legislation now passed, Mr. Ubl spoke of AdvaMed’s desire to assist Congress in reconciling them so the agreement is passed “promptly.”
Related Articles on AdvaMed:
AdvaMed Commends Congress on Progress on Reauthorization of Medical Device User Fees
AdvaMed Unveils Three-Year Strategic Policy and Advocacy Plan
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
